Uncertain About HCV, Vertex Doubles Down On CF, Looks To Sell Off Pipeline Assets

As it nears a crucial inflexion point for its hepatitis C business, Vertex shifts focus to building on its strong early start in cystic fibrosis. The Boston-area firm plans to out-license its mid-stage candidates for autoimmune disease and influenza A.